Austin, TX 12/10/2007 11:25:28 PM
Speak with other shareholders about: (NYSE: FRE), (NASDAQ: SGMO), (NASDAQ: MITI), (NASDAQ: ENMD), (AMEX: ETQ), (NASDAQ: TSRA)
Are you looking to speak with other investors about your favorite stock? Stockwire.com, ranked in the top 5,000 websites in the United States by Alexa.com/Amazon.com, has created one of the finest chat programs available for investors. Now you can chat real-time with like-minded individuals about your favorite stock. Visit Stockwire.com and click the Chat Live button at the top.
----------------------------------------------------------
Chat real-time with other investors about this FRE news release,
by clicking this link: http://www.stockwire.com/FRE
To view in-depth research, click the following
link: http://www.stockwire.com/detailed/analysis.php?company=FRE
FREDDIE MAC (NYSE: FRE)
Freddie Mac closed at $35.54 Friday, trading 12,460,000 shares.
COMPANY NEWS- December 10, 2007:
Freddie Mac announced that it will generally purchase mortgages that are 120 days or more delinquent from pools underlying Mortgage Participation Certificates when: 1) the mortgages have been modified; 2) a foreclosure sale occurs; 3) the mortgages are delinquent for 24 months; or 4) the cost of guarantee payments to security holders, including advances of interest at the security coupon rate, exceeds the cost of holding the nonperforming loans in its mortgage portfolio. Freddie Mac had generally purchased mortgages from P.C. pools shortly after they reach 120 days delinquency. Allowing the loans to remain in P.C. pools will provide a presentation of its financial results that better reflects Freddie Mac's expectations for future credit losses.
About Freddie Mac (NYSE: FRE)
Freddie Mac engages in mortgage purchasing, credit guarantee, and portfolio investment activities in the United States.
----------------------------------------------------------
Chat real-time with other investors about this SGMO news release,
by clicking this link: http://www.stockwire.com/SGMO
To view in-depth research, click the following
link: http://www.stockwire.com/detailed/analysis.php?company=SGMO
SANGAMO BIOSCIENCES, INC. (NASDAQ: SGMO)
Sangamo BioSciences, Inc. closed at $15.00 Friday, trading 720,500 shares.
COMPANY NEWS- December 10, 2007:
Sangamo BioSciences, Inc. announced the presentation of positive data in a mouse tumor model from its program to develop a novel cell therapy using its zinc finger DNA-binding protein nuclease (ZFN(TM)) technology for treatment of glioblastoma multiforme (GBM), a progressive and usually fatal brain cancer. According to the announcement, the data were presented at the 49th Annual Meeting of the American Society of Hematology (ASH) by Sangamo's collaborator Michael C.V. Jensen, M.D., Associate Chair, Division of Cancer Immunotherapeutics & Tumor Immunology, City of Hope.
About Sangamo BioSciences, Inc. (NASDAQ: SGMO)
Sangamo BioSciences, Inc. focuses on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification.
----------------------------------------------------------
Chat real-time with other investors about this MITI news release,
by clicking this link: http://www.stockwire.com/MITI
To view in-depth research, click the following
link: http://www.stockwire.com/detailed/analysis.php?company=MITI
MICROMET, INC. (NASDAQ: MITI)
Micromet, Inc. closed at $1.84 Friday, trading 47.300 shares.
COMPANY NEWS- December 10, 2007:
Micromet, Inc. and MedImmune, Inc. announced that they have presented new data from an ongoing Phase 1 clinical trial showing potent single-agent activity of MT103 in patients with late-stage non-Hodgkin's lymphoma (NHL). MT103, also known as MEDI-538, is a recombinant T-cell engaging antibody, or BiTE antibody targeting the CD19 antigen, which is uniquely expressed on B-cells. MT103 is currently being evaluated in Phase 1 and 2 clinical trials for the treatment of patients with various B-cell derived cancers.
About Micromet, Inc. (NASDAQ: MITI)
Micromet, Inc., a biopharmaceutical company, develops antibody-based products for cancer, inflammatory, and autoimmune diseases.
----------------------------------------------------------
Chat real-time with other investors about this ENMD news release,
by clicking this link: http://www.stockwire.com/ENMD
To view in-depth research, click the following
link: http://www.stockwire.com/detailed/analysis.php?company=ENMD
ENTREMED, INC. (NASDAQ: ENMD)
EntreMed, Inc. closed at $1.29 Friday, trading 162,500 shares.
COMPANY NEWS- December 10, 2007:
EntreMed, Inc., a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced the presentation of preclinical results for its lead Aurora kinase-angiogenesis inhibitor, ENMD-981693 The data were presented by EntreMed scientists at the American Society of Hematology Annual Meeting being held December 8-11, 2007 in Atlanta, Georgia.
About EntreMed, Inc. (NASDAQ: ENMD)
EntreMed, Inc., a clinical-stage pharmaceutical company, develops and commercializes oncology and anti-inflammatory drugs.
----------------------------------------------------------
Chat real-time with other investors about this ETQ news release,
by clicking this link: http://www.stockwire.com/ETQ
To view in-depth research, click the following
link: http://www.stockwire.com/detailed/analysis.php?company=ETQ
CORRIENTE RESOURCES, INC. (AMEX: ETQ)
Corriente Resources, Inc. closed at $5.27 Friday, trading 23,100 shares.
COMPANY NEWS- December 10, 2007:
Corriente announced that the Ministry of Environment in Ecuador has approved the Environmental Impact Assessment ("EIA") of the planned port operation in Machala, which is designed to act as a shipping facility for all Corriente copper concentrates to be produced in Ecuador. According to the announcement, Corriente owns a 27 hectare port site on the Santa Rosa Channel in Machala, which is connected to the Mirador project by a 400 km paved highway.
About Corriente Resources, Inc. (AMEX: ETQ)
Corriente Resources, Inc., a development stage company, engages in the acquisition, exploration, and development of copper and copper-gold mineral properties in Ecuador, South America.
----------------------------------------------------------
Chat real-time with other investors about this TSRA news release,
by clicking this link: http://www.stockwire.com/TSRA
To view in-depth research, click the following
link: http://www.stockwire.com/detailed/analysis.php?company=TSRA
TESSERA TECHNOLOGIES, INC. (NASDAQ: TSRA)
Tessera Technologies, Inc. closed at $42.19 Friday, trading 288,800 shares.
COMPANY NEWS- December 10, 2007:
Tessera Technologies, Inc. announced that it has filed a new complaint requesting the U.S. International Trade Commission ("ITC") investigate the unlawful importation, sale for importation and sale after importation of certain small-format BGA semiconductor packages and products that include these packages. According to the announcement, Tessera's complaint is directed at a variety of products, including certain DRAM memory chips, DRAM memory modules and computer systems incorporating such chips and modules.
About Tessera Technologies, Inc. (NASDAQ: TSRA)
Tessera Technologies, Inc. develops and licenses miniaturization technologies for the electronics industry.
--------------------------------------------------
About Stockwire:
Stockwire is a company that is pioneering a new way to research companies before you invest them. It's called a Stockumentary. A Stockumentary is a documentary on a publicly traded company. Imagine a Dateline NBC segment, but on a publicly traded company. We are the first company to ever bring this type of quality research to investors in this format.
The Stockumentary has video interviews with management, product demos, video tours of office or factory, research reports, sec filings and much more. All of this is delivered to investors in high quality video, either by mail or email.
Stockwire.com is owned by Stockwire Research Group Inc. (SRGI) and is an independent electronic publication committed to providing our readers with factual information on selected publicly traded companies.
As detailed below, this publication accepts compensation from some of the companies from which it features. To the degrees listed herein, this Newsletter should not be regarded as an independent publication. All statements and expressions are the sole opinions of the editors and are subject to change without notice. A profile, description, or other mention of a company in the Newsletter is neither an offer nor solicitation to buy or sell any securities mentioned.
While we believe all sources of information to be factual and reliable, in no way do we represent or guarantee the accuracy thereof, nor the statements made herein.
We encourage our readers to invest carefully and read the investor information available at the web sites of the Securities and Exchange Commission (SEC) at www.sec.gov and/or the National Association of Securities Dealers (NASDAQ) at www.NASDAQ.com. The NASDAQ has published information on how to invest carefully at its web site.
Readers can review all public filings by companies at the SEC's EDGAR page. www.sec.gov/edgar.shtml
Stockwire.com is an independent electronic publication committed to providing our readers with factual information on selected publicly traded companies. Stockwire.com is not a registered investment advisor or broker-dealer. All companies are chosen on the basis of certain financial analysis and other pertinent criteria with a view toward maximizing the upside potential for investors while minimizing the downside risk, whenever possible.
From time to time SRGI sells shares in the open market it receives as compensation for coverage of client companies. Since the shares are received as compensation for services as previously disclosed, and not for investment purposes, the editors do not view the sale of the shares as contradictory to any advice delivered in the content. This should be viewed as a conflict of interest by shareholders or prospective shareholders of the client companies.
Moreover, as detailed below, this publication accepts compensation from third party consultants and/or companies which it features on Stockwire.com.
THE READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK.
We often receive compensation in the form of stock options, in which case we receive the right to buy shares of the stock of the company at issue, at a specified time and a specified price. On occasion, we also accept free-trading shares in a company that we cover. We intend to sell these shares into the open market.
While our policies as detailed above are designed to minimize any impact upon our members of a conflict of interest between our company and our members, each member should be fully aware that such potential and actual conflicts of interest may well exist due to the compensation structure detailed herein. For this reason, and because the information contained on Stockwire.com is updated on a regular basis as circumstances change, each member is strongly encouraged to periodically review the Profile Compensation section at http://www.stockwire.com/disclaimer_profiles.htm .
The Stockwire Group .
512.358.8440 .
info@stockwire.com .
